Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Rottey, Sylvie; Clarke, Jeffrey; Aung, Kyaw Lwin; Machiels, Jean‐Pascal; Markman, Ben; Heinhuis, Kimberley M.; Millward, Michael; Lolkema, Martijn P.; Patel, Sandip Pravin; Souza, Paul de; Duca, Matteo; Curigliano, Giuseppe; Santoro, Armando; Koyama, Takafumi; Brown, Michelle; Vezina, Heather; He, Chunsheng; Chu, Quincy Siu-Chung

doi:10.1158/1078-0432.ccr-21-1181

Cited by 26 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the preclinical research, the combination of BMS-986148 with anti-programmed death-1 mAb nivolumab upgrades the antitumor impacts as the PD-1 expression hinders the T-cell activating process and expanding prior activated cells. Hence, the surrounding PD-1 route through nivolumab reinstates and progresses antitumor T-cell activity and enhances cytokine production, resulting in progressed clinical results in advanced solid tumors [ 135 ]. Tanner et al.…”

Section: Nanoscale Drug Carriermentioning

confidence: 99%

Nanoscale bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates for selective cancer therapy

Zhang¹,

Ganjali

Afruzi

et al. 2022

Heliyon

View full text Add to dashboard Cite

Section: Nanoscale Drug Carriermentioning

confidence: 99%

Nanoscale bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates for selective cancer therapy

Zhang¹,

Ganjali

Afruzi

et al. 2022

Heliyon

View full text Add to dashboard Cite

“…In the absence of further therapeutic strategies, the patient was enrolled in a phase I-II clinical trial with the combination of BMS-986148, a mesothelin-directed antibody drug conjugate (ADC), and Nivolumab (April 2017) [20]. After three cycles of therapy the patient experienced grade-3 ascites.…”

Section: Case Presentationmentioning

confidence: 99%

Uterine Tumor Resembling Sex-Cord Tumors of the Ovary (Utrosct): A Case of Long-Term Response to Pazopanib

2022

Ann Case Report

View full text Add to dashboard Cite

Background: uterine tumor resembling sex-cord tumors of the ovary (UTROSCT) is a rare form of mesenchymal uterine tumor of uncertain malignancy. Sporadic cases of advanced disease are reported, but little is known about its management in the metastatic setting. Pazopanib is a multi-tyrosine kinase inhibitor (TKI), approved for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcomas, which affects several targets, including VEGFR1-2-3, PDGFRα-β and FGFR1-3. Case presentation: here we report a case of metastatic UTROSCT with strong and prolonged clinical response to pazopanib. Conclusions: these findings suggest that this anti-angiogenic approach should be considered in planning future therapeutic strategies for this rare disease. Furthermore, we noted the importance of including patients with rare diseases in clinical trials and investigating molecular pathogenesis.

show abstract

“…The ORR and DCR were 9% and 13%, respectively, including two PRs (DOR, 19.91 and 3.02 months) and 11 SDs among 22 ovarian cancer patients, with a PFS of 2.8 months. There were also seven PDs ( Rottey et al, 2022 ).…”

Section: Use Of Adcs In Gynecologic Cancermentioning

confidence: 99%

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

et al. 2022

View full text Add to dashboard Cite

Immune checkpoint inhibitors have made significant progress in the treatment of various cancers. However, due to the low ICI responsive rate for the gynecologic cancer, ICI two-drug combination therapy tends to be a predominant way for clinical treatment. Antibody-drug conjugates, a promising therapeutic modality for cancer, have been approved by the FDA for breast cancer, lymphoma, multiple myeloma and gastric cancer. On September 2021, the FDA granted accelerated approval to tisotumab vedotin for patients with recurrent or metastatic cervical cancer. Currently, the role of therapy of ADCs on gynecologic tumors was also included in medication regimens. Now more than 30 ADCs targeting for 20 biomarkers are under clinical trials in the field, including monotherapy or combination with others for multiple lines of therapy. Some ADCs have been proved to enhance the antitumor immunity effect on both pre-clinical models and clinical trials. Therefore, combination of ADCs and ICIs are expected in clinical trials. In this review, we discuss current development of ADCs in gynecologic oncology and the combination effects of ICIs and ADCs.

show abstract

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Cited by 26 publications

References 42 publications

Nanoscale bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates for selective cancer therapy

Nanoscale bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates for selective cancer therapy

Uterine Tumor Resembling Sex-Cord Tumors of the Ovary (Utrosct): A Case of Long-Term Response to Pazopanib

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

Contact Info

Product

Resources

About